Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - neoplażmi tat-tirojde - aġenti antineoplastiċi - trattament ta 'pazjenti adulti b'karċinoma medjulari tat-tirojde progressiva, li ma tistax tiġi mneħħija lokalment jew metastatika.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

bristol-myers squibb / pfizer eeig - apixaban - arthroplasty; venous thromboembolism - aġenti antitrombotiċi - għal eliquis 2. 5 mg pilloli miksija b'rita:il-prevenzjoni ta 'każi trombo-emboliċi venużi (vte) f'pazjenti adulti li kellhom operazzjoni mhux urġenti tal-ġenbejn jew operazzjoni tas-sostituzzjoni ta' l-irkoppa. il-prevenzjoni ta 'puplesija u emboliżmu sistematiku f'pazjenti adulti b'nuqqas valvulari fibrillazzjoni atrijali (nvaf), ma'wieħed jew aktar fatturi ta' riskju, bħal qabel puplesija jew attakk iskemiku temporanju (tia); età ≥ 75-il sena; pressjoni għolja; d-dijabete mellitus; insuffiċjenza tal-qalb sintomatika (nyha klassi ≥ ii). trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti (ara sezzjoni 4. 4 għall-emodinamikament instabbli pe pazjenti). għal eliquis 5 mg pilloli miksija b'rita:il-prevenzjoni tal-puplesija u emboliżmu sistematiku f'pazjenti adulti b'nuqqas valvulari fibrillazzjoni atrijali (nvaf), ma'wieħed jew aktar fatturi ta ' riskju, bħal qabel puplesija jew attakk iskemiku temporanju (tia); età≥ 75-il sena; pressjoni għolja; d-dijabete mellitus; insuffiċjenza tal-qalb sintomatika (nyha klassi ≥ ii). trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti (ara sezzjoni 4. 4 għall-emodinamikament instabbli pe pazjenti).

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

novartis europharm limited - interferon beta-1b - sklerosi multipla - immunostimulanti, - extavia huwa indikat għall-kura ta': pazjenti b'avveniment wieħed demyelinating bi proċess infjammatorju attiv, jekk ikun sever biżżejjed li jkun jeħtieġ il-kura b'kortikosterojdi ġol-vina, jekk dijanjosi alternattivi kienu esklużi, u jekk kien stabbilit li huma f'riskju għoli li jiżviluppaw sklerożi multipla klinikament definita;pazjenti bi sklerożi multipla li tirkadi u tbatti l-isklerożi multipla u żewġ jew aktar attakki reċidivi fi żmien l-aħħar sentejn;il-pazjenti bi sklerożi multipla progressiva sekondarja bil-marda attiva, evidenzjata mill-irkadar.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

photonamic gmbh & co. kg - idroklorur ta 'l-aċidu 5-aminolevuliniku - glioma - aġenti antineoplastiċi - gliolan huwa indikat f'pazjenti adulti għall-viżwalizzazzjoni ta 'tessut malinn waqt il-kirurġija għal glijoma malinna (l-organizzazzjoni dinjija tas-saħħa grad iii u iv).

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - iressa huwa indikat għall-kura ta 'pazjenti adulti b'lokalment avvanzat jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelluli tal-kanċer b'mutazzjonijiet li jattivaw tal-epidermali-tkabbir tal-fattur-riċetturi ta' tyrosine kinase.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, tromboċitopenika, idjopatika - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulanti, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 u 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. fir-rigward tal-deċiżjoni li tinbeda l-kura f'pazjenti pedjatriċi ara sezzjonijiet 4. 2, 4. 4 u 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 u 5. għall-vajrus tal-epatite Ċ (hcv) ġenotip attività speċifika, ara sezzjonijiet 4. 2 u 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. meta jiddeċiedu li tibda l-kura fit-tfulija, huwa importanti li tikkunsidra l-inibizzjoni tat-tkabbir indotta mill-terapija kombinata. l-riversibbiltà ta ' inibizzjoni tat-tkabbir huwa inċert. id-deċiżjoni li l-kura għandha tittieħed fuq bażi ta'każ b'każ (ara sezzjoni 4.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - neoplażmi kolorettali - aġenti antineoplastiċi - kura tal-kanċer metastatiku tal-kolorektum (mcrc).

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - antineoplastic agents, protein kinase inhibitors - gefitinib mylan huwa indikat bħala monoterapija għall-kura ta 'pazjenti adulti b'lokalment avvanzat jew dak metastatiku li mhux ta' ċelluli żgħar kanċer tal-pulmun (nsclc) b'mutazzjonijiet li jattivaw ta ' egfr‑tk.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - aġenti antitrombotiċi - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. il-prevenzjoni ta 'puplesija u emboliżmu sistematiku f'pazjenti adulti b'nuqqas valvulari fibrillazzjoni atrijali (nvaf), ma'wieħed jew aktar fatturi ta' riskju, bħal qabel puplesija jew attakk iskemiku temporanju (tia); età ≥ 75-il sena; pressjoni għolja; d-dijabete mellitus; insuffiċjenza tal-qalb sintomatika (nyha klassi ≥ ii). trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti (ara sezzjoni 4. 4 għall-emodinamikament instabbli pe pazjenti). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti (ara sezzjoni 4. 4 għall-emodinamikament instabbli pe pazjenti).